Sintilimab
- Generic Name
- Sintilimab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2072873-06-2
- Unique Ingredient Identifier
- 8FU7FQ8UPK
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Evaluate Sintilimab Plus Lenvatinib as Adjuvant Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis (PVTT) After Surgical Resection
- Conditions
- Interventions
- First Posted Date
- 2023-10-18
- Last Posted Date
- 2023-10-18
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 104
- Registration Number
- NCT06089382
- Locations
- 🇨🇳
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
bTAE-HAIC Combined With Lenvatinib and Sintilimab for Infiltrative Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-10-06
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 30
- Registration Number
- NCT06070636
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Perioperative Sintilimab Plus Bevacizumab Biosimilar and TACE-HAIC for HCC Patients With PVTT: A Phase-2 Clinical Trial
- First Posted Date
- 2023-09-11
- Last Posted Date
- 2023-09-11
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 43
- Registration Number
- NCT06031285
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
The Clinical Significance of Peripheral Blood T Lymphocyte PD-1 Expression and T Cell Subset Distribution.
- First Posted Date
- 2023-09-08
- Last Posted Date
- 2023-09-08
- Lead Sponsor
- Xin-Hua Xu
- Target Recruit Count
- 60
- Registration Number
- NCT06029829
- Locations
- 🇨🇳
Department of Medical Oncology, Central Hospital of Yichang City, the First Clinical Medical College of Three Gorges University, Yichang, Hubei, China
Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma
- First Posted Date
- 2023-08-28
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 30
- Registration Number
- NCT06013618
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Propranolol Hydrochloride in Combination With Sintilimab and Platinum-based Chemotherapy for Treatment of Advanced Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-08-07
- Last Posted Date
- 2024-11-19
- Target Recruit Count
- 6
- Registration Number
- NCT05979818
- Locations
- 🇨🇳
The Second Xiangya Hospital of Central south University, Changsha, Hunan, China
A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-08-04
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 668
- Registration Number
- NCT05976568
- Locations
- 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China
🇨🇳Nanjing Tianyinshan Hospital, Nanjing, Jiangsu, China
Phase II Study of Fruquintinib Combined With Sintilimab and TACE for Inoperable Primary Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-08-02
- Last Posted Date
- 2023-08-02
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 27
- Registration Number
- NCT05971199
- Locations
- 🇨🇳
Guoliang Shao, Hangzhou, Zhejiang, China
A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-06-06
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 360
- Registration Number
- NCT05890742
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
The Combination of Radiotherapy，Surufatinib and Sintilimab in High-Risk Localized Soft Tissue Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2023-05-03
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 52
- Registration Number
- NCT05839275
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.